I
GF-1 is considered a prototypical trophic factor produced locally in many tissues including the brain (paracrine function) and is also secreted into the bloodstream to target distant tissues as part of the somatotrophic axis (hormonal function) (1) . Furthermore, it has been demonstrated that serum IGF-1 is able to cross the blood-brain barriers under physiological conditions, depending on neuronal activity. This novel mechanism evidenced the existence of a neurotrophic coupling accompanying the more classical neurovascular coupling (2) . Therefore, it seems that there are two different sources for brain IGF-1 that constitute two relatively separated compartments whose functional relationship remains to be further investigated.
In the adult, circulating IGF-1 has been observed to promote neuroprotection in response to brain injury and neurodegeneration, to mediate the positive effects of exercise on the brain, and to impact on cognitive processing, including learning and memory (1) . Moreover, studies in humans have identified a correlation of serum IGF-1 with cognition based on the association of agerelated cognitive dysfunction and the physiological decline of circulating IGF-1 during normal aging (3) .
In contrast, observations stemming from invertebrate models of aging using partial ablation of insulin-like peptide receptors showed that this signaling pathway negatively impacts on the life span (4). These findings have been largely confirmed in higher species (5) and eventually led to the notion that the reduction of the IGF-1 receptor (IGF-1R) is beneficial in age-related diseases (6) . More recently, IGF-1R reduction in the brain has been shown to protect against different types of pathologies, including Alzheimer's-like amyloidosis (7) (8) (9) . As seen in many cases of ligand-receptor feedback regulation, a likely explanation of this apparent contradiction is that IGF-1 may be down-regulating brain IGF-1R (10) . Indeed, it has already been shown that IGF-1 modulates the expression of IGF-1R in different types of cells (11, 12) , and we previously reported that elevated IGF-1Rs in the brains of Alzheimer disease mice were normalized by exogenous IGF-1 treatment (13) . In the present work, we analyzed the effect of IGF-1 on brain IGF-1R expression, both in vitro and in vivo, and found that IGF-1 modulates it.
Materials and Methods

Animals
Male adult C57BL/6J mice (25-30 g, 8-9 wk old; Harlan Laboratories) were housed in standard cages (48 3 26 cm 2 ) with five animals per cage. Mice were kept in a room with controlled temperature (22°C) under a 12-hour light, 12-hour dark cycle and fed with a pellet rodent diet and water ad libitum. All experimental protocols were performed during the light cycle except when analyzing environmental enrichment in which an inverse cycle was used to ensure optimal physiological conditions of the animals. Animal procedures followed European guidelines (86/609/EEC and 2003/65/EC, European Council Directives) and were approved by the local bioethics committee. Chronic sc administration of human IGF-1 (hIGF-1; Pre-Protech, 50 mg/kg$d) was performed using polylactic, polyglutamic microspheres loaded with IGF-1, as previously described in detail (14) . In brief, mice received a single sc injection of microsphere suspended in saline containing hIGF-1 (1.4 mg/kg body weight). The relative content of hIGF-1 in the microsphere was 3%. Mice were killed 2 hours and 1, 2, 5, 10 15, and 20 days after the injection (five to six mice at each time point). Animals were deeply anesthetized with sodium pentobarbital, and cerebrospinal fluid was collected by cisternal puncture. Then blood was collected by cardiac puncture and serum separated. Finally, the forebrain was quickly dissected out. All samples were stored at -80°C until analysis. Control mice (n 5 5) received no microsphere injection. Alternatively, chronic sc administration of hIGF-1 (50 mg/kg$d) was carried out with Alzet osmotic minipumps following the manufacturer's instructions. Finally, a bolus systemic injection of hIGF-1 (100 mg/kg) was performed. Mice (n 5 8 per group) were deeply anesthetized with pentobarbital (50 mg/kg) and injected ip with IGF-1 or saline. After 1-6 hours, mice were transcardially perfused with 0.9% saline and their hippocampi processed for IGF-1 and IGF-1/IGF-1R mRNA measurement, as detailed below.
Cell cultures
Brain endothelial cells, neurons, astrocytes, microglia, and oligodendroglia were isolated from early postnatal rats and cultured in vitro, as already described in detail (2, 15, 16) . Glia and endothelium were obtained from the cortex, whereas neurons were collected from the cerebellum. When reaching confluence, cells were serum starved and stimulated with recombinant human IGF-1 (100 nM) for 6, 15, or 30 hours or remained on serum-free media (untreated controls). Finally, cells were washed with PBS (pH 7.4) before RNA extraction, as explained below.
Immunoassays IGF-1 in mouse serum and tissue was determined using a murine ELISA (R&D Systems), as described (17) . Blood was collected from the heart after pentobarbital anesthesia before transcardiac perfusion. hIGF-1 levels were measured by a human ELISA (R&D Systems). IGF-1R levels were measured by Western blot (WB). WB and immunoprecipitation were performed as described (18) . In brief, tissue samples were homogenized in lysis buffer (pH 7.4) (10 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail). Lysates were centrifuged to remove any insoluble material and incubated overnight with agarose-conjugated rabbit anti-IGF-1R antibody (see Table 1 ). Next, agarose beads (with the immunocomplexes attached) were centrifuged and washed three times with lysis buffer diluted 1:2 in distilled water. Finally, beads were resuspended on loading buffer, boiled, and assayed by SDS-PAGE. After transfer to membranes, these were incubated with anti-pTyr antibody (Table 1) .
RNA extraction and quantitative PCR (qPCR)
A standard guanidinium thiocyanate-phenol-chloroform extraction was carried out in harvested cells or tissue samples with Trizol (Ambion). Purified RNA was reconstituted in nucleasefree water (not diethylpyrocarbonate treated; Ambion), and its concentration and quality were assessed through a NanoDrop spectrophotometer (Thermo Scientific). RNA samples were retrotranscribed to cDNA using the high-capacity cDNA reverse transcription kit (Applied Biosystems) and then assayed directly by qPCR or stored at 220°C until further use. To determine the relative gene expression of target genes, we used Taqman gene expression assays (IGF-1: Mm00439560_m1 and Rn00710306_m1; IGF-1R: Mm00802831_m1 and Rn00583837_m1) plus an additional measurement of 18S ribosomal RNA as an endogenous control. Each sample was run in triplicate on a 7000/7500 real-time PCR system (Applied Biosystems), according to the following programming: 2 minutes at 50°C (one cycle), 10 minutes at 95°C (one cycle), 15 seconds at 95°C, and 1 minute at 60°C (40 cycles). Off-line analysis for the determination of relative mRNA quantity was performed using a modified 2(-ddcycle threshold) method, as described elsewhere (19) . Results depict the fold increase of relative mRNA expression in experimental groups with respect to controls.
IGF-1 receptor gene reporter
We generated pIGF-1R LUC cells, a stable IGF-1 receptor gene reporter cell line using the C6 rat glioma following a protocol using puromycin selection (see http://www.cincinnatichildrens. org/research/cores/lenti/background-protocol/). Briefly, cells were infected with lentiviral particles expressing the pEZX-LvPG02 vector (GeneCopoeia) with the IGF-1R promoter inserted downstream of Gaussia luciferase. Luciferase activity in cell supernatants collected 24 hours after the addition of hIGF-1 (1 nM) was measured in a luminometer (Berthold).
Environmental enrichment
Animals were kept under inverted circadian cycle conditions for 1 week before enrichment (dark: 5:00 AM to 5:00 PM; light: 5:00 PM to 5:00 AM). Then they were split into two groups: control animals, which remained under standard housing conditions (370-530 cm 2 cage, two to five mice per cage and no objects), and enriched animals, placed for up to 1 month in a large cage (1815 cm 2 ), 10 animals/cage and with different objects (cardboard tunnels, shelters of different materials, a plastic net, toys, chewable and nesting material). At the end of each time interval, animals were anesthetized with pentobarbital and perfused with saline. Samples were collected, immediately frozen, and stored at -80°C until further processing.
Statistical analysis
Analyses were carried out using the GraphPad Prism 5 software. For in vitro assays, a minimum of three different experiments in duplicate/triplicate was run. The number of animals for the in vivo experiments is indicated in each case. After confirming normal distribution with the KolmogorovSmirnov test and equal variances with the Levene's test, we used the Student's t test for comparing two groups or a oneway ANOVA for more than two groups, followed by Bonferroni's multiple comparison test as a post hoc test. Graphs show mean 6 SEM; P values are coded as follows: *, P , .05, **, P , .01, and ***, P , .001.
Results
IGF-1 inhibits IGF-1R in cultured brain cells
Because previous evidence indicated that IGF-1 downregulates the expression of IGF-1R in neuroblastoma cells (12), we analyzed its effect in the major types of brain cells. Exposure of cultured primary neurons, astrocytes, brain endothelial cells, oligodendrocytes, or microglia to IGF-1 resulted in significantly decreased IGF-1R mRNA levels, as determined by qPCR ( Figure 1A) . A similar inhibitory effect of IGF-1 was seen in a glioma cell line expressing a luciferase-IGF-1R gene reporter ( Figure 1B) , confirming previous observations of a direct regulatory effect on IGF-1R promoter activity (11) . Levels of IGF-1R protein were similarly lowered after the exposure of astrocytes to IGF-1 ( Figure 1C) , reinforcing a functional impact of IGF-1 on its receptor. We also observed a Dashed lines denote control levels (n $ 3 for each type of culture). *, P , .05, **, P , .01, ***, P , .001 vs control. B, IGF-1 diminishes IGF-1R promoter activity in C6 glioblastoma cells as determined using a luciferase-based gene reporter system. *, P , .05. C, IGF-1 decreases IGF-1R protein levels. WB of astrocytes after 6 hours of adding IGF-1 (1 and 100 nM) is shown. Representative blot is shown (n 5 4). **, P , .01. D, IGF-1 significantly decreased IGF-1 mRNA in neurons, BECs, and microglia (in this latter cell type only at longer times), whereas in astrocytes it elicited a changing pattern (n $ 3 for each type of culture). *, P , .05, **, P , .01, ***, P , .001 vs control). Dashed lines denote control levels. press.endocrine.org/journal/endogenerally inhibitory effect of IGF-1 on its own expression in neurons and endothelial cells ( Figure 1D ).
IGF-1 modulates IGF-1R in the brain
To determine the in vivo actions of IGF-1, we injected hIGF-1 systemically, a procedure that results in its entrance into the brain and cerebrospinal fluid (Supplemental Figure 1A ), as already published (14) . A bolus ip injection of hIGF-1 (150 mg/kg) resulted in a prompt stimulation of hippocampal IGF-1R phosphorylation (Figure 2A ), a quick reduction of endogenous IGF-1 levels ( Figure 2B ), together with a significant increase in its mRNA ( Figure 2C) , and an increase in IGF-1R mRNA without changes in protein levels ( Figure 2D ). However, after 10 days of continued hIGF-1 infusion (50 mg/kg$d), brain IGF-1 and IGF-1R mRNAs were unaltered (Supplemental Figure 1B) .
To further characterize the in vivo actions of IGF-1, we took advantage of previous observations showing that environmental enrichment (EE) promotes the entrance of serum IGF-1 into the brain and stimulates its receptor in different brain areas, including the hippocampus (2, 20, 21) . As previously observed (2), increased hippocampal IGF-1R phosphorylation was seen after 2 hours of placing the mice in EE conditions, returning to basal levels by 6 hours ( Figure 3, A and B) . This temporal pattern of IGF-1R phosphorylation was paralleled by IGF-1R protein levels ( Figure 3C ). After IGF-1R activation, a continuous decrease in brain IGF-1 levels, peaking at 6 hours of EE, was observed ( Figure 3D ). This decrease was accompanied by significant increases in IGF-1 and IGF-1R mRNA levels at this time point (Figure 3, A and D) . After 24 hours of EE, both IGF-1R and IGF-1 mRNA levels normalize, despite increased IGF-1R phosphorylation, reflecting increased activity of the pathway (Figure 3, A and D) . After 1 month of EE, only brain IGF-1 levels were slightly increased ( Figure 3D ).
Discussion
The present results indicate that although IGF-1 inhibits the expression of its receptor in cultured brain cells, in response to a physiological or pharmacological increase in IGF-1 input to the brain, IGF-1R activity is transiently increased. Detailed analysis of this apparent contradictory finding clarifies it. Thus, entrance of serum IGF-1 into the brain sets in motion a step-wise process that we consider is directed to spatiotemporally limit the action of serum IGF-1 input into the brain. Whereas in vitro exposure of brain cells to IGF-1 resulted in a decreased expression of its receptor for more than 1 day, in vivo, in which brain architecture and endogenous regulatory mechanisms remain intact, exposure to increased IGF-1 by stimulating its entrance from serum elicited increased IGF-1R expression that return to baseline levels within 1 day. Time-course analysis of this in vivo process revealed a rapid clearance/degradation of brain IGF-1 soon after IGF-1R activity was increased in response to the increased serum IGF-1 input. This rapid elimination translated into lowering levels of brain IGF-1 that concurred with a higher expression of brain IGF-1R (and IGF-1, see below). Hence, brain IGF-1R is under regulation by IGF-1, possibly as part of a constitutive homeostatic regulatory mechanism as under normal conditions it seems that IGF-1 restrains IGF-1R expression because when brain IGF-1 levels decrease, IGF-1R levels increase. However, the inhibitory action of IGF-1 is transient because IGF-1R levels are eventually normalized through an as-yet-undetermined feedback process. A summary of the proposed mechanism is shown in Figure 4 .
The existence of a regulatory feedback between entrance of serum IGF-1 and brain IGF-1R activity is reinforced by the observation that in mutant mice with low serum IGF-1 levels (LID mice), brain IGF-1R activity is altered, probably because entrance of serum IGF-1 in LID mice is impaired (21) . Importantly, LID mice present several pathological changes in brain function (17) . Along this line, we reported that IGF-1 treatment in APP/ PS2 mice, a model of Alzheimer disease, normalized abnormally high IGF-1R levels in the brain (13), Thus, it is possible that in pathology, the mechanism that normalizes brain IGF-1R levels after exposure to IGF-1 is disturbed, and neuroprotection is achieved by lowering IGF-1R levels. In other words, in pathology, the inhibitory actions of IGF-1 onto its receptor may be abnormally prolonged. This possibility would require further study. Collectively these observations indicate press.endocrine.org/journal/endothat brain IGF-1R activity is finely tuned and that IGF-1 can modulate it. The present observations also point to a functional interaction between circulating and brain IGF-1 through inhibition of its own synthesis in several brain cell types. In vivo, increased serum IGF-1 input to the brain, as indicated by an increased phosphorylation of its receptor, led to a rapid and gradual reduction in brain IGF-1 levels. Importantly, and as seen in cultured neurons and endothelia, a negative action of IGF-1 onto its own synthesis was also observed, ie, low brain IGF-1 levels were paralleled by increased brain IGF-1 expression. Whereas mechanisms leading to reduced brain IGF-1 levels after brain stimulation by environmental enrichment remain to be clarified, it has been reported that neuronal activity stimulates microglia that, in turn, releases proteases such as cathepsins (22) , These peptidases may be involved in the degradation of IGF-1 (23), although treatment of microglial cells with IGF-1 did not modify the mRNA levels of cathepsin S (not shown). Again, further work is warranted. At any rate, others have reported that brain activity stimulates local production of IGF-1 in specific cell types (24, 25) .
Collectively this is the first report showing that IGF-1 and its receptor in the brain are regulated by circulating IGF-1. These findings open more questions but establish the existence of a regulatory loop between systemic IGF-1 and brain IGF-1/IGF-1R that may be disturbed in pathology. In response to neuronal activation, serum IGF-1 enters into the brain and activates its receptor (2). This is followed by a gradual decrease in brain IGF-1 levels and an eventual transient increase in brain IGF-1R expression. Through an as yet-unknown feedback mechanism (?), IGF-1R levels return to baseline. We speculate that this mechanism controls in a spatiotemporal manner the action of IGF-1 upon its activitydependent entrance from serum.
